Share on LinkedInShare on LinkedIn

ARTICLE · 02 JANUARY 2026

CVS PBM Caremark Appeals $290M Overbilling Judgment

CVS Caremark, the pharmacy benefits manager (PBM) for CVS, has filed a notice of appeal of a $290 million judgment in a lawsuit alleging that it overbilled for Medicare Part...

United StatesEmployment and HR

CVS Caremark, the pharmacy benefits manager (PBM) for CVS, has filed a notice of appeal of a $290 million judgment in a lawsuit alleging that it overbilled for Medicare Part D-sponsored drugs. The judgment was increased from $95 million to $290 million in August 2025 in an order from a Pennsylvania federal district court that included treble damages for Caremark's "serious" misconduct under the False Claims Act. The judge increased the damages in large part because of Caremark's "financially motivated" fraud, rather than an innocent or mistaken belief.

Whistleblower and former Aetna head actuary Sarah Behnke filed suit against Caremark in 2014, alleging that Caremark overbilled the federal government by $240 to $330 million. Behnke alleged that Caremark violated federal law that requires PBMs to report "pass-through" prices, leading to millions in fraudulent Medicare claims dating back to 2007. Caremark purportedly failed to report its Generic Effective Rate (GER)

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from